Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients

European Journal of Haematology

Volumn 82, Issue 4, 2009, Pages 292-300

  Bianchini, Michele ^a   Brasi, Carlos De ^a   Gargallo, Patricia ^a   Gonzalez, Mariana ^a   Bengió, Raquel ^a   Larripa, Irene ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib mesylate; Overexpression; Treatment resistance

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 61349085373     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01199.x     Document Type: Article

References (21)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960 132 : 1499 504.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999 341 : 164 72.
3. Druker Bj, Tammura S, Buchdunger E, Ohno S, Segal Gm, Fanning S, Zimmermannn J, Lydon Nb. Effect of a selective inhibitor of the Abl Tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 2 : 561 6.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 355 : 2408 17.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P, Sawyers C. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutations or amplification. Science 2001 293 : 876 80.
6. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006 20 : 1767 73.
7. Le Coutre P, Tassi E, Varella-García M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 95 : 1758 66.
8. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002 16 : 2190 6.
9. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000 92 : 1641 50.
10. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002 9 : 303 7.
11. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004 103 : 4010 22.
12. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddermann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002 16 : 53 9.
13. Wang Y, Bagg A, Pear W, Nowell P, Hess J. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer 2001 32 : 97 111.
14. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology 1993 11 : 1026 30.
15. Kim YJ, Kim DW, Lee S, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002 68 : 272 80.
16. Chomel JC, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, Guilhot F, Brizard A. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alfa therapy or allogeneic bone marrow transplantation. Blood 2000 95 : 404 9.
17. Tabone S, The'ou N, Wozniak A, et al. Kit overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta 2005 1741 : 165 72.
18. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG. Relation between resístanse of Philadelphia-chromosome- positive acute lymphoblastic leukemia to the tyrosine kinase inhibitor STI571 and gene expression profiles: a gene-expression study. Lancet 2002 359 : 481 6.
19. Kreil S, Muller C, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood 2001 98 : 435a (abstr 1823).
20. Gambacorti-Passerini C, Gunby R, Piazza R, Galieta A, Rostagno R, Scapozza L. Molecular mechanisms of resistanse to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003 4 : 75 85.
21. Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001 98 : 3864 7.